small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 58 results

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Industry

Artificial Intelligence (AI)

Practice Area

Privacy: Regulated Personal Information (RPI)

Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond....Read more

Experience 150 results

Experience

|

December 11, 2025

Winston Takes the Checkered Flag After “Massive Win” Settlement

Winston squared off in the W.D.N.C. against lawyers for NASCAR in an antitrust lawsuit brought on behalf of racing teams Front Row Motorsports Inc. and 23X1 Racing LLC—the team co-owned by Michael Jordan and driver Denny Hamlin—alleging monopolization of the market for premier stock car racing teams. On December 11, 2025, nine days into trial and the morning after the plaintiffs rested their case, the parties jointly announced a settlement. Jeffrey Kessler, Jeanifer Parsigian, and Danielle Williams were recognized by American Lawyer with its top “Litigator of the Week” honors on December 19, 2025, for this historic settlement....Read more

Experience

|

December 3, 2025

US Tiger Securities Announced IPO

Winston & Strawn LLP is serving as U.S. securities counsel to US Tiger Securities, Inc., a full-service broker/dealer, in connection with the $10,000,000 initial public offering of SMJ International Holdings Inc., a Singapore-based premium flooring specialist. The Company priced 2,500,000 Class A ordinary shares at US$4.00 per share. The Class A ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “SMJF” on December 4, 2025....Read more

Experience

|

October 1, 2025

AA Mission Acquisition Corp. II - Initial Public Offering

Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025....Read more
View All Experience

Insights & News 1,490 results

Competition Corner

|

December 23, 2025

|

4 Min Read

The Continuing Expansion of Algorithmic Software Laws – Best Practices for Companies in an Evolving Landscape

New York recently expanded its algorithmic pricing laws, now requiring retailers to disclose when prices are set with algorithmic software based on consumers’ personal data.The so-called practice of surveillance pricing entails adjusting prices charged for goods and services according to monitored personal data.

Capital Markets & Securities Law Watch

|

December 18, 2025

|

5 Min Read

Chairman Atkins’ NYSE Speech and the SEC’s 2026 Examination Priorities: A Reset for U.S. Capital Markets

Two recent developments signal where the Securities and Exchange Commission (the SEC) is headed in 2026. First, SEC Chairman Paul Atkins’ address at the New York Stock Exchange (NYSE) on December 2, 2025 set forth guiding principles for reform with the goal to, in Chairman Atkins’ words, “make IPOs great again.”

Competition Corner

|

December 17, 2025

|

3 Min Read

Antitrust Remedies in United States v. Google: AI and the Evolving Search Market

Following the August 5, 2024, decision in United States v. Google where the D.C. District Court found Google to be a monopolist, Judge Amit Mehta issued what would end up being the first remedies opinion on September 2, 2025. The decision establishes a six-year framework designed to promote competition in the general search engine market. 

View All Insights & News

Other Results 68 results

Law Glossary

What Is a Qualified Retirement Plan?

A qualified retirement plan is a retirement plan established by an employer that is designed to provide retirement income to designated employees and their beneficiaries, which meets certain IRS Code requirements in terms of both form and operation. Common plan types are 401(k) plans, pension plans, and profit-sharing plans. A qualified retirement plan may allow for both employer and employee contributions. Employers must follow procedures to ensure participants and beneficiaries are able to receive their benefits. They must also stay apprised of changes in retirement plan laws and regulations. Qualified retirement plans provide certain tax advantages to employers and tax deferral advantages to employees who are contributing. Taxes on earnings from the contributions are also deferred until the employee withdraws them from the plan....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more

Law Glossary

What Is a Biologic?

A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)...Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising